SCHEMBL273256

SCHEMBL273256

Cc1cccc(/C=N/NC(=O)c2cc(Br)ccc2NC(=O)c2ccco2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.60
PKM P14618 4/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
RAB9A P51151 7/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
KDM4E B2RXH2 5/20 0.50
TUBB8B A6NNZ2 1/20 0.50
EGFR P00533 1/20 0.50
TUBB4A P04350 1/20 0.50
TUBB P07437 1/20 0.50
TUBA3C P0DPH7 1/20 0.50
TUBA1B P68363 1/20 0.50
TUBA4A P68366 1/20 0.50
TUBB4B P68371 1/20 0.50
TUBB3 Q13509 1/20 0.50
TUBB2A Q13885 1/20 0.50
TUBB8 Q3ZCM7 1/20 0.50
TUBA3E Q6PEY2 1/20 0.50
TUBA1A Q71U36 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268158 1.00 NPC1 (0.60) NPC1PKMMEN1KMT2ARAB9A
SCHEMBL273871 0.90 NPC1 (0.67) NPC1PKMMEN1KMT2ARAB9A
SCHEMBL266600 0.90 NPC1 (0.67) NPC1PKMMEN1KMT2ARAB9A
SCHEMBL273869 0.89 NPC1 (0.60) NPC1PKMMEN1KMT2ARAB9A
SCHEMBL273286 0.89 NPC1 (0.58) NPC1PKMMEN1KMT2ARAB9A
SCHEMBL268693 0.89 NPC1 (0.58) NPC1PKMMEN1KMT2ARAB9A
SCHEMBL265031 0.89 NPC1 (0.60) NPC1PKMMEN1KMT2ARAB9A
SCHEMBL266761 0.85 RAB9A (0.54) NPC1PKMMEN1KMT2ARAB9A
SCHEMBL274298 0.85 RAB9A (0.54) NPC1PKMMEN1KMT2ARAB9A
SCHEMBL273626 0.84 KMT2A (0.62) NPC1PKMMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 NPC1 115/4885PKM 1916/4885MEN1 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.